Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Astegolimab - Genentech

Next Previous
Drug Profile

Astegolimab - Genentech

Alternative Names: AMG-282; Anti-ST2; MSTT 1041 A; RG 6149; RO 7187807; ST2 MAb

Latest Information Update: 16 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Genentech; Roche
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Allergic asthma; Atopic dermatitis
  • Discontinued Asthma; COVID-19 pneumonia; Rhinosinusitis

Most Recent Events

  • 20 May 2026 Efficacy and adverse events data from a phase III trial in Chronic obstructive pulmonary disease presented at the 122nd International Conference of the American Thoracic Society (ATS-2026)
  • 01 Oct 2025 Adverse events and pharmacokinetics data from a phase I trial in healthy colunteers presented at the 35th Annual Congress of the European Respiratory Society (ERS-2025)
  • 01 Oct 2025 Efficacy and adverse events data from a phase IIb ALIENTO trial in Chronic obstructive pulmonary disease were presented at the 35th Annual Congress of the European Respiratory Society (ERS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top